Explore

Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus

Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus

Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus
Trendline Trendline
FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma

FDA Decision on Replimune's RP1 Drug Could Signal Regulatory Direction for Biopharma
Trendline Trendline
Takeda Ends Partnership with Denali, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali, Returns Dementia Drug Rights
Trendline Trendline
Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights
Trendline Trendline
ImmunityBio Responds to FDA Concerns, Enhances Advertising Compliance Measures

ImmunityBio Responds to FDA Concerns, Enhances Advertising Compliance Measures

ImmunityBio Responds to FDA Concerns, Enhances Advertising Compliance Measures
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market
Trendline Trendline
enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization

enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization

enGene Therapeutics Inc. Announces Name Change Reflecting Transition to Commercial Organization
Trendline Trendline
Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline
Trendline Trendline
Corcept Therapeutics Faces Securities Fraud Lawsuit Led by Rosen Law Firm

Corcept Therapeutics Faces Securities Fraud Lawsuit Led by Rosen Law Firm

Corcept Therapeutics Faces Securities Fraud Lawsuit Led by Rosen Law Firm
Trendline Trendline
FDA Warns Medvi Over Misleading Marketing Practices Amid Telehealth Expansion

FDA Warns Medvi Over Misleading Marketing Practices Amid Telehealth Expansion

FDA Warns Medvi Over Misleading Marketing Practices Amid Telehealth Expansion